Genzyme will pay $325 million up front for the powerful drug mipomersen, an antisense treatment that slashes cholesterol levels. Credit: Genzyme ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Genzyme, a Sanofi company, has won its second approval for its multiple sclerosis drug, aubagio, to be used in Australia. After winning approval in the United States back in September, Sanofi ...

Genzyme ran into a snag in April when the US Food and Drug Administration (FDA) rejected its application to produce Myozyme (alglucosidase alfa, rhGAA) in its 2,000–liter-scale facility under ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

"We are honored to welcome Dr. Ekuta to our Life Sciences Strategic Advisory Board," said Girish Pashilkar, CEO of BP Logix. ...

Dottie Caplan, who previously served as Senior Vice President, Patient Advocacy and Engagement, will be responsible for leading Applied’s patient engagement and advocacy efforts as well as the ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, ... The drug was first approved by the FDA in atopic dermatitis in 2017, ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.